1例信迪利单抗致免疫相关性结肠炎分析与处置  

Analysis and management of a case of sintilimab-induced immune-related colitis

作　　者：谢希晖 宋霞[2] XIE Xihui;SONG Xia(Department of Pharmacy,Shanghai General Hospital Jiuquan Hospital(Jiuquan People’s Hospital),Gansu Jiuquan 735000,China;Department of Pharmacy,Lanzhou University Second Hospital,Gansu Lanzhou 730030,China)

机构地区：[1]上海市第一人民医院酒泉医院(酒泉市人民医院)药剂科,甘肃酒泉735000 [2]兰州大学第二医院药剂科,甘肃兰州730030

出　　处：《中国医院药学杂志》2025年第3期359-362,共4页Chinese Journal of Hospital Pharmacy

摘　　要：该文报道了1例因肺肉瘤样癌接受信迪利单抗致G4级免疫相关性结肠炎患者的诊疗过程。治疗过程中对信迪利单抗引起免疫相关性结肠炎发生机制、临床表现进行分析,从最初考虑感染性腹泻到药物相关性肠炎,经过抗感染、调节肠道菌群及纠正电解质紊乱治疗效果欠佳,最终给予甲基泼尼松龙治疗后患者好转。该报道旨在进一步提高临床医师及药师对免疫相关不良反应的认识,增加免疫检查点抑制剂临床应用经验。This article reported the diagnosis and treatment process of a patient with G4 grade immune-related colitis caused by sintilimab treatment for pulmonary sarcomatoid carcinoma.During the treatment process,an analysis was conducted on the mechanism and clinical manifestations of sintilimab-induced immune-related colitis.From initially considering infectious diarrhea to drug-induced enteritis,the treatment effect was unsatisfactory after anti-infection,regulation of gut microbiota,and correction of electrolyte imbalance.Finally,the patient was improved by methylprednisolone.This case report aims to further enhance the understanding of immune-related adverse events among clinical physicians and pharmacists,and increase the clinical application experience of immune checkpoint inhibitors.

关 键 词：临床药师 信迪利单抗 腹泻 免疫相关性结肠炎 

分 类 号：R969.3[医药卫生—药理学]